Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 8, 2004, Pages 3629-3643

  Hull, Rebecca L ^a   Westermark, Gunilla T ^b   Westermark, Per ^c   Kahn, Steven E ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; AMYLOID A PROTEIN; APOLIPOPROTEIN E; C PEPTIDE; CALCITONIN RECEPTOR; CALCIUM; CONGO RED; GLUCAGON; GLUCOSE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; IMMUNOGLOBULIN LIGHT CHAIN; INSULIN; INSULINASE; MESSENGER RNA; MONOMER; ORAL ANTIDIABETIC AGENT; PARAPROTEIN; PRAMLINTIDE; PREALBUMIN; PROINSULIN; PROTEIN P21; PROTEIN P53; PROTEOHEPARAN SULFATE; RECEPTOR ACTIVITY MODIFYING PROTEIN; SERUM AMYLOID P; THIOFLAVINE;

AGING; AMINO ACID SEQUENCE; AMYLOIDOSIS; ANIMAL EXPERIMENT; APOPTOSIS; AREA POSTREMA; ARTICLE; AUTOPSY; B LYMPHOCYTE; BETA SHEET; BODY WEIGHT; CELL DEATH; CELL FUNCTION; CELL SIZE; CHRONIC INFLAMMATION; CLEARANCE; CYTOTOXICITY; DISEASE ASSOCIATION; ELECTRON MICROSCOPY; FAT INTAKE; FOOD INTAKE; GENE CONTROL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; MICROSCOPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEUS ACCUMBENS; OBESITY; OXIDATIVE STRESS; PANCREAS BIOPSY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PEPTIDE SYNTHESIS; PH; POINT MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN SECRETION; SOLITARY TRACT NUCLEUS; TRANSGENIC ANIMAL; UPREGULATION;

AMYLOID; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; ISLETS OF LANGERHANS;

ANIMALIA;

EID: 4043171124     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-0405     Document Type: Article

References (225)

1. Westermark P 1972 Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 77:91-94
2. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJS, Holman RR, Turner RC 1988 Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type-2 diabetes. Diabetes Res 9:151-159
3. Westermark P 1994 Amyloid and polypeptide hormones: what is their interrelationship? Amyloid 1:47-60
4. Kahn SE, Andrikopoulos S, Verchere CB 1999 Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253
5. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC 2003 β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110
6. Opie EL 1901 The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islets of Langerhans. J Exp Med 5:527-540
7. Weichselbaum A, Stangl E 1901 Zur Kenntis der feineren Veränderungen des Pankreas bei Diabetes mellitus. Wien Klin Wochenschr 14:968-972
8. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH 1987 Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84:3881-3885
9. Westermark P, Wernstedt C, Wilander E, Sletten K 1986 A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 140:827-831
10. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM 1987 Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628-8632
11. Tan SY, Pepys MB 1994 Amyloidosis. Histopathology 25:403-414
12. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD 2002 Amyloid fibril protein nomenclature: 2002. Amyloid 9:197-200
13. Glenner GG, Ein D, Terry WD 1972 The immunoglobulin origin of amyloid. Am J Med 52:141-147
14. Benditt EP, Eriksen M, Hermodsen MA, Ericsson LH 1971 The major proteins of human and monkey amyloid substance: common properties including unusual N-terminal sequences. FEBS Lett 19:169-173
15. Saraiva MJM, Birken S, Costa PP, Goodman DS 1984 Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type: definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 74:104-119
16. Westermark P, Sletten K, Johansson B, Cornwell III GG 1990 Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 87:2843-2845
17. Westermark P, Wilander E 1978 The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15:417-421
18. Glenner GG, Wong CW 1984 Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885-890
19. Glenner GG, Wong CW, Quaranta V, Eanes ED 1984 The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol 2:357-369
20. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K 1985 Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245-4249
21. Sletten K, Westermark P, Natvig JB 1976 Characterisation of amyloid fibril proteins from medullary carcinoma of the thyroid. J Exp Med 143:993-998
22. Cohen AS, Calkins E 1959 Electron microscopic observation on a fibrous component in amyloid of diverse origins. Nature 183:1202-1203
23. Eanes ED, Glenner GG 1968 X-Ray diffraction studies on amyloid filaments. J Histochem Cytochem 16:673-677
24. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CCF 1997 Common core structure of amyloid fibrils by synchrotron x-ray diffraction. J Mol Biol 273:729-739
25. Sumner Makin O, Serpell LC 2004 Structural characterisation of islet amyloid polypeptide fibrils. J Mol Biol 335:1279-1288
26. Schwartz P 1965 Über Amyloidose des Gehrins, der Langerhansschen Inseln und des Hertzens alter Personen. Zbl Allg Path Anat 108:169-187
27. Kelenyi G 1967 Thioflavin S fluorescent and Congo red anisotropic stainings in the histologic demonstration of amyloid. Acta Neuropathol (Berl) 7:336-348
28. Stiller D, Katenkamp D 1970 Fluorescence optical demonstration of amyloid by means of thioflavin S. Zentralbl Allg Pathol 113:451-465
29. Levine H 1995 Thioflavine-T interaction with amyloid β-sheet structures. Amyloid 2:1-6
30. Puchtler H, Sweat F, Levine M 1962 On the binding of Congo Red by amyloid. J Histochem Cytochem 10:355-364
31. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG 2003 Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489
32. Porat Y, Kolusheva S, Jelinek R, Gazit E 2003 The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 42:10971-10977
33. Shirahama T, Cohen AS 1967 High resolution electron microscopic analysis of the amyloid fibril. J Cell Biol 33:679-706
34. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC 1999 The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491-498
35. Westermark P, Wilander E, Westermark GT, Johnson KH 1987 Islet amyloid polypeptide-like immunoreactivity in the islet B-cells of type-2 (non-insulin-dependent) diabetic and non-diabetic individuals. Diabetologia 30:887-892
36. Johnson KH, O'Brien TD, Hayden DW, Jordan K, Ghobrial HKG, Mahoney WC, Westermark P 1988 Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic β-cells by means of peroxidase antiperoxidase (PAP) and protein-A-gold techniques. Am J Pathol 130:1-8
37. Clark A, Edwards CA, Ostle LR, Sutton R, Rothbard JB, Morris JF, Turner RC 1989 Localization of islet amyloid peptide in lipofuscin bodies and secretory granules of human β-cells and in islets of type-2 diabetic subjects. Cell Tissue Res 257:179-185
38. Lukinius A, Wilander E, Westermark GT, Engström U, Westermark P 1989 Co-localization of islet amyloid polypeptide and insulin in the B-cell secretory granules of the human pancreatic-islets. Diabetologia 32:240-244
39. Sanke T, Bell GI, Sample C, Rubenstein AH, Steiner DF 1988 An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing. J Biol Chem 263:17243-17246
40. Nishi M, Sanke T, Seino S, Eddy RL, Fan YS, Byers MG, Shows TB, Bell GI, Steiner DF 1989 Human islet amyloid polypeptide gene: complete nucleotide-sequence, chromosomal localization, and evolutionary history. Mol Endocrinol 3:1775-1781
41. Betsholtz C, Svensson V, Rorsman F, Engström U, Westermark GT, Wilander E, Johnson K, Westermark P 1989 Islet amyloid polypeptide (IAPP): cDNA cloning and identification of an amyloidogenic region associated with the species-specific occurrence of age-related diabetes-mellitus. Exp Cell Res 183:484-493
42. Badman MK, Shennan KIJ, Jermany JL, Docherty K, Clark A 1996 Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett 378:227-231
43. Higham CE, Hull RL, Lawrie L, Shennan KI, Morris JF, Birch NP, Docherty K, Clark A 2000 Processing of synthetic pro-islet amyloid polypeptide (proIAPP) 'amylin' by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem 267:4998-5004
44. 2-terminal cleavage site. Diabetes 50:534-539
45. Marzban L, Trigo-Gonzalez G, Zhu X, Rhodes CJ, Halban PA, Steiner DF, Verchere CB 2004 Role of β-cell prohormone convertase (PC)1/3 in processing of pro-islet amyloid polypeptide. Diabetes 53:141-148
46. Bailyes EM, Shennan KIJ, Seal AJ, Smeekens SP, Steiner DF, Hutton JC, Docherty K 1992 A member of the eukaryotic subtilisin family (PC3) has the enzymatic-properties of the type-1 proinsulin-converting endopeptidase. Biochem J 285:391-394
47. Bennett DL, Bailyes EM, Nielsen E, Guest PC, Rutherford NG, Arden SD, Hutton JC 1992 Identification of the type-2 proinsulin processing endopeptidase as PC2, a member of the eukaryote subtilisin family. J Biol Chem 267:15229-15236
48. Roberts AN, Leighton B, Todd JA, Cockburn D, Schofield PN, Sutton R, Holt S, Boyd Y, Day AJ, Foot EA, Willis AC, Reid KBM, Cooper GJS 1989 Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc Natl Acad Sci USA 86:9662-9666
49. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ, Porte Jr D 1990 Evidence of co-secretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39:634-638
50. Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D, Chang JK, Rizza RA 1990 Effects of meal ingestion on plasma amylin concentration in NIDDM and non-diabetic humans. Diabetes 39:752-756
51. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, Prager R 1991 Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34:52-54
52. Kahn SE, Fujimoto WY, D'Alessio DA, Ensinck JW, Porte Jr D 1991 Glucose stimulates and potentiates islet amyloid polypeptide secretion by the β-cell. Horm Metab Res 23:577-580
53. Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H, Matsukara S 1992 Plasma islet amyloid polypeptide levels in obesity, impaired glucose-tolerance and non-insulin-dependent diabetes-mellitus. Diabetes Res Clin Pract 15:97-102
54. Hanabusa T, Kubo K, Oki C, Nakano Y, Okai K, Sanke T, Nanjo K 1992 Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 15:89-96
55. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhausl W, Prager R 1994 Role of islet amyloid polypeptide secretion in insulin resistant humans. Diabetologia 37:188-194
56. Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G 1996 Integrated mathematical model to assess β-cell activity during the oral glucose test. Am J Physiol 33:E522-E531
57. Leckström A, Björklund K, Permert J, Larsson R, Westermark P 1997 Renal elimination of islet amyloid polypeptide. Biochem Biophys Res Commun 239:265-268
58. Dechenes CJ, Verchere CB, Andrikopoulos S, Kahn SE 1998 Human aging is associated with parallel reductions in insulin and amylin release. Am J Physiol 38:E785-E791
59. Kahn SE, Verchere CB, Andrikopoulos S, Asberry PJ, Leonetti DL, Wahl PW, Boyko EJ, Schwartz RS, Newell-Morris L, Fujimoto WY 1998 Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47:640-645
60. Knowles NG, Landchild MA, Fujimoto WY, Kahn SE 2002 Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 25:292-297
61. Novials A, Sarri Y, Casamitjana R, Rivera F, Gomis R 1993 Regulation of islet amyloid polypeptide in human pancreatic islets. Diabetes 42:1514-1519
62. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte Jr DJ 1993 Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663-1672
63. Clark A, Saad MF, Nezzer T, Uren C, Knowler WC, Bennett PH, Turner RC 1990 Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33:285-289
64. Kautzky-Willer A, Thomaseth K, Ludvik B, Nowotny P, Rabensteiner D, Waldhausl W, Pacini G, Prager R 1997 Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes 46:607-614
65. Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, Kondo M, Nanjo K 1991 Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type-2 (non-insulin-dependent) diabetic-patients. Diabetologia 34:129-132
66. Ludvik B, Lell B, Hartter E, Schnack C, Prager R 1991 Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 40:1615-1619
67. Makimattila S, Fineman MS, Yki-Jarvinen H 2000 Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes. J Clin Endocrinol Metab 85:2822-2827
68. Leighton B, Cooper GJS 1988 Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal-muscle in vitro. Nature 335: 632-635
69. Sowa R, Sanke T, Hirayama J, Tabata H, Furuta H, Nishimura S, Nanjo K 1990 Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia 33:118-120
70. Silvestre RA, Peiro E, Degano P, Miralles P, Marco J 1990 Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Regul Pept 31:23-31
71. Degano P, Silvestre RA, Salas M, Peiro E, Marco J 1993 Amylin inhibits glucose-induced insulin-secretion in a dose-dependent manner: study in the perfused rat pancreas. Regul Pept 43:91-96
72. Ohsawa H, Kanatsuka A, Yamaguchi T, Makino H, Yoshida S 1989 Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun 160:961-967
73. Åkesson B, Panagiotidis G, Westermark P, Lundquist I 2003 islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets. Regul Pept 111:55-60
74. Gebre-Medhin S, Mulder H, Pekny M, Westermark GT, Tornell J, Westermark P, Sundler F, Ahren B, Betsholtz C 1998 Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun 250:271-277
75. Kong MF, King P, Macdonald IA, Stubbs TA, Perkins AC, Blackshaw PE, Moyses C, Tattersall RB 1997 Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 40:82-88
76. Kolterman OG, Gottlieb A, Moyses C, Colburn W 1995 Reduction of post-prandial hyperglycemia in subjects with IDDM by intravenous-infusion of AC137, a human amylin analog. Diabetes Care 18:1179-1182
77. Thompson RG, Peterson J, Gottlieb A, Mullane J 1997 Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes 46:632-636
78. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA 2000 Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol 278:G946-G951
79. Chance WT, Balasubramaniam A, Zhang FS, Wimalawansa SJ, Fischer JE 1991 Anorexia following the intrahypothalamic administration of amylin. Brain Res 539:352-354
80. Chance WT, Balasubramaniam A, Stallion A, Fischer JE 1993 Anorexia following the systemic injection of amylin. Brain Res 607:185-188
81. Lutz TA, Senn M, Althaus J, DelPrete E, Ehrensperger F, Scharrer E 1998 Lesion of the area postrema nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides 19:309-317
82. Arnelo U, Herrington MK, Theodorsson E, Adrian TE, Reidelberger R, Larsson J, Marcusson J, Strommer L, Ding X, Permert J 2000 Effects of long-term infusion of anorexic concentrations of islet amyloid polypeptide on neurotransmitters and neuropeptides in rat brain. Brain Res 887:391-398
83. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, D'Alessio DA, Air EL, Woods SC 2001 Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 142:5035-5038
84. Beaumont K, Kenney MA, Young AA, Rink TJ 1993 High affinity amylin binding sites in rat brain. Mol Pharmacol 44:493-497
85. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K1 1994 In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62:553-567
86. Aiyar N, Baker E, Martin J, Patel A, Stadel JM, Willette RN, Barone FC 1995 Differential calcitonin-gene-related peptide (CGRP) and amylin binding-sites in nucleus-accumbens and lung: potential models for studying CGRP/amylin receptor subtypes. J Neurochem 65:1131-1138
87. Wookey PJ, Tikellis C, Du HC, Qin HF, Sexton PM, Cooper ME 1996 Amylin binding in rat renal-cortex, stimulation of adenylyl-cyclase, and activation of plasma-renin. Am J Physiol 39:F289-F294
88. Harris PJ, Cooper ME, Hiranyachattada S, Berka JL, Kelly DJ, Nobes M, Wookey PJ 1997 Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney. Am J Physiol 41:F13-F21
89. Chai SY, Christopoulos G, Cooper ME, Sexton PM 1998 Characterization of binding sites for amylin, calcitonin, and CGRP in primate kidney. Am J Physiol 43:F51-F62
90. Gilbey SG, Ghatei MA, Bretherton-Watt D, Zaidi M, Jones PM, Perera T, Beacham J, Girgis S, Bloom SR 1991 Islet amyloid polypeptide: production by an osteoblast cell-line and possible role as a paracrine regulator of osteoclast function in man. Clin Sci 81:803-808
91. Alam A, Moonga BS, Bevis PJR, Huang CLH, Zaidi M 1993 Amylin inhibits bone-resorption by a direct effect on the motility of rat osteoclasts. Exp Physiol 78:183-196
92. Brain SD, Wimalawansa S, Macintyre I, Williams TJ 1990 The demonstration of vasodilator activity of pancreatic amylin amide in the rabbit. Am J Pathol 136:487-490
93. Chin SY, Hall JM, Brain SD, Morton IKM 1994 Vasodilator responses to calcitonin-gene-related peptide (CGRP) and amylin in the rat isolated-perfused kidney are mediated via CGRP(1) receptors. J Pharmacol Exp Ther 269:989-992
94. Muff R, Buhlmann N, Fischer JA, Born W 1999 An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology 140:2924-2927
95. Tilakaratne N, Christopoulos G, Zumpe ET, Foord SM, Sexton PM 2000 Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther 294:61-72
96. Oliver KR, Kane SA, Salvatore CA, Mallee JJ, Kinsey AM, Koblan KS, Keyvan-Fouladi N, Heavens RP, Wainwright A, Jacobson M, Dickerson IM, Hill RG 2001 Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat. Eur J Neurosci 14:618-628
97. Hall JM, Brain SD 1999 Interaction of amylin with calcitonin gene-related peptide receptors in the microvasculature of the hamster cheek pouch in vivo. Br J Pharmacol 126:280-284
98. Cornish J, Gallon KE, Lin CQ, Xiao CL, Gamble GD, Cooper GJ, Reid IR 1999 Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts. J Bone Miner Res 14:1302-1309
99. Hasbak P, Opgaard OS, Eskesen K, Schifter S, Arendrup H, Longmore J, Edvinsson L 2003 Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist. J Pharmacol Exp Ther 304:326-333
100. Westermark P, Engström U, Johnson KH, Westermark GT, Betsholtz C 1990 Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036-5040
101. Moriarty DF, Raleigh DP 1999 Effects of sequential proline substitutions on amyloid formation by human amylin(20-29). Biochemistry 38:1811-1818
102. Azriel R, Gazit E 2001 Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation. J Biol Chem 276:34156-34161
103. Sakagashira S, Sanke T, Hanabusa T, Shimomura H, Ohagi S, Kumagaye KY, Nakajima K, Nanjo K 1996 Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 45:1279-1281
104. Sakagashira S, Hiddinga HJ, Tateishi K, Sanke T, Hanabusa T, Nanjo K, Eberhardt NL 2000 S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin. Am J Pathol 157:2101-2109
105. Ma Z, Westermark GT, Sakagashira S, Sanke T, Gustavsson A, Sakamoto H, Engström U, Nanjo K, Westermark P 2001 Enhanced in vitro production of amyloid-like fibrils from mutant (S20G) islet amyloid polypeptide. Amyloid 8:242-249
106. Nilsson MR, Raleigh DP 1999 Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin. J Mol Biol 294:1375-1385
107. Jaikaran ET, Higham CE, Serpell LC, Zurdo J, Gross M, Clark A, Fraser PE 2001 Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis. J Mol Biol 308:515-525
108. Jaikaran ET, Clark A 2001 Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 1537:179-203
109. Ma Z, Westermark GT, Li ZC, Engström U, Westermark P 1997 Altered immunoreactivity of islet amyloid polypeptide (IAPP) may reflect major modifications of the IAPP molecule in amyloidogenesis. Diabetologia 40: 793-801
110. Porte Jr D, Kahn SE 1989 Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet β-cell dysfunction? Diabetes 38:1333-1336
111. Chargé SBP, de Koning EJP, Clark A 1995 Effect of pH and insulin on fibrillogenesis of islet amyloid polypeptide in-vitro. Biochemistry 34:14588-14593
112. Westermark P, Li ZC, Westermark GT, Leckström A, Steiner DF 1996 Effects of β-cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett 379:203-206
113. Westermark GT, Gebre-Medhin S, Steiner DF, Westermark P 2000 Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol Med 6:998-1007
114. Janciauskiene S, Eriksson S, Carlemalm E, Ahren B 1997 B-cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro. Biochem Biophys Res Commun 236:580-585
115. Jaikaran ET, Nilsson MR, Clark A 2004 Pancreatic β-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem J 377:709-716
116. Larson JL, Miranker AD 2004 The mechanism of insulin action on islet amyloid polypeptide fiber formation. J Mol Biol 335:221-231
117. Duckworth WC, Bennett RG, Hamel FG 1998 Insulin degradation: progress and potential. Endocr Rev 19:608-624
118. Becker AB, Roth RA 1995 Insulysin and pitrilysin: insulin-degrading enzymes of mammals and bacteria. Methods Enzymol 248:693-703
119. Duckworth WC 1988 Insulin degradation: mechanisms, products, and significance. Endocr Rev 9:319-345
120. Kurochkin IV 2001 Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem Sci 26:421-425
121. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ 2000 Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J Neurosci 20:1657-1665
122. Bennett RG, Duckworth WC, Hamel FG 2000 Degradation of amylin by insulin-degrading enzyme. J Biol Chem 275:36621-36625
123. Bennett RG, Hamel FG, Duckworth WC 2003 An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes 52:2315-2320
124. Kapurniotu A, Bernhagen J, Greenfield N, Al Abed Y, Teichberg S, Frank RW, Voelter W, Bucala R 1998 Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide. Eur J Biochem 251:208-216
125. Hull RL, Andrikopoulos S, Verchere CB, Vidal J, Wang F, Cnop M, Prigeon RL, Kahn SE 2003 Increased dietary fat promotes islet amyloid formation and β-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52:372-379
126. Ma Z, Westermark GT 2002 Effects of free fatty acid on polymerization of islet amyloid polypeptide (IAPP) in vitro and on amyloid fibril formation in cultivated isolated islets of transgenic mice overexpressing human IAPP. Mol Med 8:863-868
127. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte Jr D 1987 Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 30:698-702
128. Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y 1988 Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31:355-360
129. Saad MF, Kahn SE, Nelson RG, Pettitt DJ, Knowler WC, Schwartz MW, Kowalyk S, Bennett PH, Porte Jr D 1990 Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 70:1247-1253
130. Kahn SE, Halban PA 1997 Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46: 1725-1732
131. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY 1995 Proinsulin as a marker for the development of NIDDM in Japanese-American men. Diabetes 44:173-179
132. Mykkanen L, Haffner SM, Hales CN, Ronnemaa T, Laakso M 1997 The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes 46: 1990-1995
133. Hull RL, Jaikaran ETAS, Serpell LC, Fraser PE, Clark A, Landon M 1999 Human pro-islet amyloid polypeptide forms amyloid-like fibrils in vitro and could promote amyloidosis in diabetes. In: Kyle RA, Gertz MA, eds. Amyloid and amyloidosis 1998. New York: Parthenon; 542-544
134. Krampert M, Bernhagen J, Schmucker J, Horn A, Schmauder A, Brunner H, Voelter W, Kapurniotu A 2000 Amyloidogenicity of recombinant human pro-islet amyloid polypeptide (proIAPP). Chem Biol 7:855-871
135. Westermark GT, Steiner DF, Gebre-Medhin S, Engström U, Westermark P 2000 Pro islet amyloid polypeptide (ProIAPP) immunoreactivity in the islets of Langerhans. Ups J Med Sci 105:97-106
136. Westermark P, Eizirik DL, Pipeleers DG, Hellerstrom C, Andersson A 1995 Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia 38:543-549
137. Westermark G, Westermark P, Eizirik DL, Hellerstrom C, Fox N, Steiner DF, Andersson A 1999 Differences in amyloid deposition in islets of transgenic mice expressing human islet amyloid polypeptide versus human islets implanted into nude mice. Metab Clin Exp 48:448-454
138. Kahn SE 2001 The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047-4358
139. de Koning EJP, Höppener JWM, Verbeek JS, Oosterwijk C, van Hulst KL, Baker CA, Lips CJM, Morris JF, Clark A 1994 Human islet amyloid polypeptide accumulates at similar sites in islets of transgenic mice and humans. Diabetes 43:640-644
140. Jarrett JT, Lansbury PT 1993 Seeding one-dimensional crystallization of amyloid: a pathogenic mechanism in Alzheimers disease and scrapie. Cell 73:1055-1058
141. Mirzabekov TA, Lin MC, Kagan BL 1996 Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem 271:1988-1992
142. Harroun TA, Bradshaw JP, Ashley RH 2001 Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Lett 507:200-204
143. Anguiano M, Nowak RJ, Lansbury PTJ 2002 Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41:11338-11343
144. Snow AD, Wight TN 1989 Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging 10:481-497
145. Ohsawa H, Kanatsuka A, Tokuyama Y, Yamaguchi T, Makino H, Yoshida S, Horie H, Mikata A, Kohen Y 1991 Amyloid protein in somatostatinoma differs from human islet amyloid polypeptide. Acta Endocrinol (Copenh) 124:45-53
146. Young ID, Ailles L, Narindrasorasak S, Tan R, Kisilevsky R 1992 Localization of the basement membrane heparan sulfate proteoglycan in islet amyloid deposits in type-II diabetes mellitus. Arch Pathol Lab Med 116:951-954
147. Wisniewski T, Frangione B 1992 Apolipoprotein-E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135: 235-238
148. Pepys MB, Rademacher TW, Amatayakulchantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, Nelson SR, Gallimore JR, Herbert J, Hutton T, Dwek RA 1994 Human serum amyloid-P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 91:5602-5606
149. Chargé SBP, Esiri MM, Bethune CA, Hansen BC, Clark A 1996 Apolipoprotein-E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease. J Pathol 179:443-447
150. Vidal J, Verchere CB, Andrikopoulos S, Wang F, Hull RL, Cnop M, Olin KL, LeBoeuf RC, O'Brien KD, Chait A, Kahn SE 2003 The effect of apolipoprotein E deficiency on islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Diabetologia 46:71-79
151. Togashi S, Lim SK, Kawano H, Ito S, Ishihara T, Okada Y, Nakano S, Kinoshita T, Horie K, Episkopou V, Gottesman ME, Costantini F, Shimada K, Maeda S 1997 Serum amyloid P component enhances induction of murine amyloidosis. Lab Invest 77:525-531
152. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD 1993 Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649-9653
153. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM 1997 Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 17:263-264
154. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM 1999 Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 96:15233-15238
155. Eto M, Watanabe K, Makino I, Ishii K 1991 Apolipoprotein E allele frequencies in non-insulin-dependent diabetes mellitus with hypertriglyceridemia (type IIb, III, IV, and V hyperlipoproteinemia). Metabolism 40:776-780
156. Inamdar PA, Kelkar SM, Devasagayam TP, Bapat MM 2000 Apolipoprotein E polymorphism in non-insulin-dependent diabetics of Mumbai, India and its effect on plasma lipids and lipoproteins. Diabetes Res Clin Pract 47:217-223
157. Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E 1997 Amyloid P component. A critical review. Amyloid-Int J Exp Clin Invest 4:274-295
158. Potter-Perigo S, Hull RL, Tsoi C, Braun KR, Andrikopoulos S, Teague JC, Verchere CB, Kahn SE, Wight TN 2003 Proteoglycans synthesized and secreted by pancreatic islet β-cells bind amylin. Arch Biochem Biophys 413: 182-190
159. Watson DJ, Lander A.D, Selkoe DJ 1997 Heparin-binding properties of the amyloidogenic peptices A-β and amylin: dependence on aggregation state and inhibition by Congo red. J Biol Chem 272:31617-31624
160. Castillo GM, Cummings JA, Yang WH, Judge ME, Sheardown MJ, Rimvall K, Hansen JB, Snow AD 1998 Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes 47:612-620
161. Hull RL, Potter-Perigo S, Kahn SE, Wight TN 2003 Pancreatic islet β-cells produce and secrete heparan sulfate proteoglycans that specifically bind amyloidogenic human islet amyloid polypeptide. Diabetes 52(Suppl 1):A377
162. Park K, Verchere CB 2001 Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide. Implications for islet amyloid formation. J Biol Chem 276:16611-16616
163. McCubbin WD, Kay CM, Narindrasorasak S, Kisilevsky R 1988 Circular-dichroism studies on two murine serum amyloid A proteins. Biochem J 256:775-783
164. Yankner BA, Duffy LK, Kirschner DA 1990 Neurotrophic and neurotoxic effects of amyloid β-protein: reversal by tachykinin neuropeptides. Science 250:279-282
165. May PC, Boggs LN, Fuson KS 1993 Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimers-disease amyloid-β neurotoxicity. J Neurochem 61:2330-2333
166. Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y, Kimura H 1995 Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci USA 92:1989-1993
167. Lorenzo A, Razzaboni B, Weir GC, Yankner BA 1994 Pancreatic islet cell toxicity of amylin associated with type 2 diabetes mellitus. Nature 368:756-760
168. 2+ in apoptosis evoked by human amylin in pancreatic islet β-cells. Biochem J 343:53-61
169. Saafi EL, Konarkowska B, Zhang S, Kistler J, Cooper GJ 2001 Ultrastructural evidence that apoptosis is the mechanism by which human amylin evokes death in RINm5F pancreatic islet β-cells. Cell Biol Int 25:339-350
170. Tucker HM, Rydel RE, Wright S, Estus S 1998 Human amylin induces "apoptotic" pattern of gene expression concomitant with cortical neuronal apoptosis. J Neurochem 71:506-516
171. Zhang S, Liu J, Saafi EL, Cooper GJ 1999 Induction of apoptosis by human amylin in RINm5F islet "-cells is associated with enhanced expression of p53 and p21WAF1/CIP1. FEBS Lett 455:315-320
172. Wang F, Hull RL, Vidal J, Cnop M, Kahn SE 2001 Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50:2514-2520
173. Tenidis K, Waldner M, Bernhagen J, Fischle W, Bergmann M, Weber M, Merkle ML, Voelter W, Brunner H, Kapurniotu A 2000 Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. J Mol Biol 295:1055-1071
174. Janciauskiene S, Ahren B 1998 Different sensitivity to the cytotoxic action of IAPP fibrils in two insulin-producing cell lines, HIT-T15 and RINm5F cells. Biochem Biophys Res Commun 251:888-893
175. Janciauskiene S, Ahren B 2000 Fibrillar islet amyloid polypeptide differentially affects oxidative mechanisms and lipoprotein uptake in correlation with cytotoxicity in two insulin-producing cell lines. Biochem Biophys Res Commun 267:619-625
176. Shearman MS, Hawtin SR, Tailor VJ 1995 The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by β-amyloid peptides. J Neurochem 65: 218-227
177. Shearman MS, Ragan CI, Iversen LL 1994 Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid- mediated cell death. Proc Natl Acad Sci USA 91:1470-1474
178. Tiedge M, Lortz S, Drinkgern J, Lenzen S 1997 Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46:1733-1742
179. Kodama K, Hull RL, Wilbur SM, Vidal J, Kahn SE 2004 Amyloid formation following islet transplantation is associated with increased β-cell apoptosis, decreased β-cell replication and reduced β-cell volume. Diabetes 53(Suppl 2):A375 (Abstract)
180. Ritzel RA, Butler PC 2003 Replication increases β-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 52:1701-1708
181. Howard Jr CF 1986 Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 29:301-306
182. de Koning EJP, Bodkin NL, Hansen BC, Clark A 1993 Diabetes-mellitus in Macaca-mulatta monkeys is characterized by islet amyloidosis and reduction in β-cell population. Diabetologia 36:378-384
183. Johnson KH, O'Brien TD, Jordan K, Westermark P 1989 Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic β-cells. Am J Pathol 135:245-250
184. Ma Z, Westermark GT, Johnson KH, O'Brien TD, Westermark P 1998 Quantitative immunohistochemical analysis of islet amyloid polypeptide (IAPP) in normal, impaired glucose tolerant, and diabetic cats. Amyloid 5:255-261
185. Fox N, Schrementi J, Nishi M, Ohagi S, Chan SJ, Heisserman JA, Westermark GT, Leckström A, Westermark P, Steiner DF 1993 Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes-mellitus (NIDDM). FEBS Lett 323:40-44
186. D'Alessio DA, Verchere CB, Kahn SE, Hoagland V, Baskin DG, Palmiter RD, Ensinck JW 1994 Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43:1457-1461
187. Yagui K, Yamaguchi T, Kanatsuka A, Shimada F, Huang CI, Tokuyama Y, Ohsawa H, Yamamura KI, Miyazaki JI, Mikata A, Yoshida S, Makino H 1995 Formation of islet amyloid fibrils in β-secretory granules of transgenic mice expressing human islet amyloid polypeptide (amylin). Eur J Endocrinol 132:487-496
188. Höppener JWM, Verbeek JS, de Koning EJP, Oosterwijk C, van Hulst KL, Visser-Vernooy HJ, Hofhuis FMA, van Gaalen S, Berends MJH, Hackeng WHL, Jansz HS, Morris JF, Clark A, Capel PJA, Lips CJM 1993 Chronic overproduction of islet amyloid polypeptide (amylin) in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycemia or hyperinsulinemia. Diabetologia 36:1258-1265
189. Verchere CB, D'Alessio DA, Palmiter RD, Kahn SE 1994 Transgenic mice overproducing islet amyloid polypeptide have increased insulin storage and secretion in vitro. Diabetologia 37:725-728
190. Bell ET 1959 Hyalinization of the islets of Langerhans in nondiabetic individuals. Am J Pathol 35:801-805
191. Chen M, Bergman RN, Pacini G, Porte Jr D 1985 Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased β-cell function. J Clin Endocrinol Metab 60:13-20
192. Schwartz RS, Shuman WP, Bradbury VL, Cain KC, Fellingham GW, Beard JC, Kahn SE, Stratton JR, Cerqueira MD, Abrass IB 1990 Body fat distribution in healthy young and older men. J Gerontol 45:M181-M185
193. Kahn SE, Larson VG, Schwartz RS, Beard JC, Cain KC, Fellingham GW, Stratton JR, Cerqueira MD, Abrass IB 1992 Exercise training delineates the importance of B-cell dysfunction to the glucose intolerance of human aging. J Clin Endocrinol Metab 74:1336-1342
194. Weyer C, Bogardus C, Mott DM, Pratley RE 1999 The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794
195. Marshall JA, Hoag S, Shetterly S, Hamman RF 1994 Dietary fat predicts conversion from impaired glucose tolerance to NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 17:50-56
196. Tsunehara CH, Leonetti DL, Fujimoto WY 1990 Diet of second-generation Japanese-American men with and without non-insulin-dependent diabetes. Am J Clin Nutr 52:731-738
197. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN 1988 Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:1163-1167
198. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Porte Jr D, Schwartz MW 1999 Reduced β-cell function contributes to impaired glucose tolerance in dogs made obese by high-fat feeding. Am J Physiol 277:E659-E667
199. Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, Kahn SE 1996 Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic β cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492-3496
200. Kahn SE, Andrikopoulos S, Verchere CB, Wang F, Hull RL, Vidal J 2000 Oophorectomy promotes islet amyloid formation in a transgenic mouse model of type II diabetes. Diabetologia 43:1309-1312
201. Rizza RA, Mandarino LJ, Gerich JE 1982 Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31:663-669
202. Beard JC, Halter JB, Best JD, Pfeifer MA, Porte Jr D 1984 Dexamethasone-induced insulin resistance enhances B-cell responsiveness to glucose level in normal men. Am J Physiol 247:E592-E596
203. Kahn SE, Horber FF, Prigeon RL, Haymond MW, Porte Jr D 1993 Effect of glucocorticoid and growth hormone treatment on proinsulin levels in humans. Diabetes 42:1082-1085
204. Couce M, Kane LA, Obrien TD, Charlesworth J, Soeller W, McNeish J, Kreutter D, Roche P, Butler PC 1996 Treatment with growth-hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and β-cell dysfunction. Diabetes 45:1094-1101
205. Klebig ML, Wilkinson JE, Geisler JG, Woychik RP 1995 Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proc Natl Acad Sci USA 92:4728-4732
206. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM 1994 Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432
207. Höppener JWM, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JHH, Vroom TM, Ahren B, Lips CJM 1999 Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42: 427-434
208. (vy)/a mice expressing human islet amyloid polypeptide. Diabetes 47:743-750
209. Westermark G, Arora MB, Fox N, Carroll R, Chan SJ, Westermark P, Steiner DF1995 Amyloid formation in response to β-cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. Mol Med 1:542-553
210. Hoenig M, Hall G, Ferguson D, Jordan K, Henson M, Johnson K, O'Brien T 2000 A feline model of experimentally induced islet amyloidosis. Am J Pathol 157:2143-2150
211. Andrikopoulos S, Verchere CB, Terauchi Y, Kadowaki T, Kahn SE 2000 β-Cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes 49:2056-2062
212. Johnson AB, Webster JM, Sum CF, Heseltine L, Argyraki M, Cooper BG, Taylor R 1993 The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 42:1217-1222
213. Zapecka-Dubno B, Czyzyk A, Dworak A, Bak MI 1999 Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin- dependent diabetes mellitus (type 2). Arzneimittelforschung 49:330-334
214. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J 1994 Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193
215. Shen Z, Hull RL, Kodama K, Carr DB, Utzschneider KM, Wang F, Kahn SE 2003 Long term rosiglitazone and metformin treatment reduce the severity of islet amyloid but do not present its formation. Diabetes 52(Suppl 1):A338
216. Lorenzo A, Yankner BA 1994 β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proc Natl Acad Sci USA 91:12243-12247
217. Tomiyama T, Kaneko H, Kataoka K, Asano S, Endo N 1997 Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem J 322:859-865
218. Kisilevsky R, Szarek WA 2002 Novel glycosaminoglycan precursors as anti-amyloid agents part II. J Mol Neurosci 19:45-50
219. Kisilevsky R, Szarek WA 2002 Novel glycosaminoglycan precursors as anti-amyloid agents. In: Fillit HM, O'Connell AW, eds. Drug discovery and development for Alzheimer's disease 2000. New York: Springer; 98-105
220. Kisilevsky R, Szarek WA, Ancsin J, Bhat S, Li Z, Marone S 2003 Novel glycosaminoglycan precursors as anti-amyloid agents, part III. J Mol Neurosci 20:291-297
221. Kapurniotu A, Schmauder A, Tenidis K 2002 Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J Mol Biol 315:339-350
222. Scrocchi LA, Chen Y, Waschuk S, Wang F, Cheung S, Darabie AA, McLaurin J, Fraser PE 2002 Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis. J Mol Biol 318:697-706
223. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE 2002 β-Cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U. S. Diabetes 51:2170-2178
224. UK Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
225. Westermark P, Engstrom U, Westermark GT, Johnson KH, Permerth J, Betsholtz C 1989 Islet amyloid polypeptide (IAPP) and pro-IAPP immunoreactivity in human islets of Langerhans. Diabetes Res Clin Pract 7:219-226